From Boston to Tokyo
The study results were completely predictive of what we saw in the clinic. The data were all replicable, and the quality was high.
[SeroScience’s] comprehensive CARPA analysis predicted that our therapy would not elicit pseudoallergy reactions in patients and gave us peace of mind upon entering clinical trials.
[SeroScience] extended their CARPA model to interface seamlessly with our device, providing key insights we could not have found elsewhere.
Janos’s [SeroScience CEO] expertise has been crucial in providing important insights for a project involving lipid nanoparticles. He brings a lifetime of expertise with the Complement cascade and various drug formulations. He is a passionate, highly dedicated scientist and I much appreciated the opportunity to work with him.
I worked with Janos [SeroScience CEO] several years ago. He provided expertise on a project that involved a new formulation of an old drug. He and his team were responsive, thoughtful, and delivered - unfortunately negative results - but I greatly valued his honesty and integrity.